Online inquiry

IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14207MR)

This product GTTS-WQ14207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14207MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15553MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ3287MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ877MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ7289MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ13978MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ3429MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ6226MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ11110MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW